



DIGITAL ACCESS TO
SCHOLARSHIP AT HARVARD
DASH.HARVARD.EDU



HARVARD LIBRARY
Office for Scholarly Communication

Combination Therapy for Human Immunodeficiency Virus-Associated Cryptococcal Meningitis: Whom, When, and Where?

The Harvard community has made this article openly available. [Please share](#) how this access benefits you. Your story matters

Citation	Siedner, Mark J., Jeffrey I. Campbell, Steve Kanters, John E. Bennett, Kristian Thorlund, Alexander C. Tsai, and Edward J. Mills. 2015. "Combination Therapy for Human Immunodeficiency Virus-Associated Cryptococcal Meningitis: Whom, When, and Where?" <i>Open Forum Infectious Diseases</i> 2 (2): ofv071. doi:10.1093/ofid/ofv071. http://dx.doi.org/10.1093/ofid/ofv071 .
Published Version	doi:10.1093/ofid/ofv071
Citable link	http://nrs.harvard.edu/urn-3:HUL.InstRepos:17295644
Terms of Use	This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Correspondence

Combination Therapy for Human Immunodeficiency Virus-Associated Cryptococcal Meningitis: Whom, When, and Where?

TO THE EDITOR—We appreciate the thoughtful comments raised by Wolbers and Day [1] in response to our article [2]. We agree with their primary point—that our meta-analysis summarized data across studies, and it is therefore best suited to evaluate study-level and not individual-level predictors of outcomes. We should have specified more clearly that our analysis is best suited for drawing inferences about relationships among patient populations, but not about individual patients. Indeed, this point is true for almost all meta-analysis, and it also applies to most individual randomized trials [3].

It is important to note that we did not intend to imply that combination amphotericin B and flucytosine conferred a benefit in patients with cryptococcal meningitis with altered mental status. Rather, in our meta-analysis, we were unable to identify a statistically significant treatment benefit across all published literature, for combination amphotericin B

with flucytosine over amphotericin B alone. Although there was some implication of a benefit from adjunctive flucytosine in a subanalysis limited to studies that included patients with altered levels of consciousness, this estimate was not statistically significant (odds ratio = 0.56; 95% confidence interval [CI], .23–1.43) (Figure 1). As such, we hypothesized in the discussion that populations with altered consciousness might be more likely to benefit from adjunctive flucytosine therapy. If this hypothesis were correct, it would require patient-level data for confirmation.

In their recent large, randomized trial, Day et al [4] demonstrated superiority of combination amphotericin B and flucytosine over amphotericin B alone at 10 weeks. They now present a subanalysis with patient-level data that suggests that those with a normal Glasgow Coma Score (GCS) appeared to derive as much benefit (if not more) from the addition of flucytosine as those with a GCS < 15. Although their study was not powered to detect differences in these subgroups, their data do lend support to the use of flucytosine in individual patients with normal mental status within their study

population. It should be noted that the overall mortality in their study was 36% at 10 weeks (and 30% among those who received amphotericin B and flucytosine combination therapy). In contrast, the only other large randomized trial to compare amphotericin B alone with amphotericin B and adjunctive flucytosine found no difference in mortality between groups at 10 weeks (6.7% versus 6.9%; relative risk = 0.97; 95% CI, .46–2.04) [5]. It is noteworthy that this other study was conducted in the United States, excluded comatose patients from enrollment, and had a lower prevalence of participants with altered mental status than the Day et al [4] study (11% vs 28%).

We believe that the contrasting data from these 2 studies are in line with our overall conclusion: that current available evidence suggests that the adjunctive use of flucytosine might be beneficial in populations with advanced disease who are at high overall risk for mortality. As Wolbers and Day [4] point out, this does not necessarily mean that patients with normal mental status will not benefit from adjunctive flucytosine, only that populations with low overall risk of mortality are less likely to




Figure 1. Forrest plot from network meta-analysis comparing odds of early (2-week) and late (10-week) mortality between combination amphotericin B and flucytosine with amphotericin B alone for human immunodeficiency virus-associated cryptococcal meningitis. Abbreviations: AmB, amphotericin B; 5FC, flucytosine; CI, confidence interval.

benefit. Unfortunately, for the time being, it appears that flucytosine is largely only available and in use in the areas of the world where the current data suggest it has the least benefit, whereas populations with the highest mortality often cannot access it [6, 7]. Indeed, the most important conclusion we draw from our study is that more data is required, across a range of patient populations and disease stages, to elucidate which drugs are needed for which patients, and to ensure that the optimal therapies are available to those who need them.

**Mark J. Siedner,^{1,2,3} Jeffrey I. Campbell,¹
Steve Kanters,^{4,5} John E. Bennett,⁶
Kristian Thorlund,⁷ Alexander C. Tsai,^{1,3,8,9} and
Edward J. Mills^{4,10}**

¹Harvard Medical School, Boston, Massachusetts;

²Division of Infectious Disease, Department of Medicine, and ³Center for Global Health, Massachusetts General Hospital, Boston,

Massachusetts; ⁴Faculty of Health Sciences, University of Ottawa, Canada; ⁵School of Population and Public Health, University of British Columbia, Vancouver, Canada; ⁶Laboratory of Clinical Infectious Diseases, National Institutes of Health, Bethesda; ⁷Faculty of Health Sciences, McMaster University, Hamilton, Canada; ⁸Division of Global Psychiatry, Massachusetts General Hospital, Boston; ⁹Mbarara University of Science and Technology, Mbarara, Uganda; and ¹⁰Stanford Prevention Research Center, Stanford University, California

References

1. Wolbers M, Day JN. Limitation of the benefit of amphotericin-flucytosine combination therapy in patients with lower conscious level – an ecological fallacy? *Open Forum Infect Dis* **2015**; 2, doi: 10.1093/ofid/ofv069.
2. Campbell JI, Kanters S, Bennett JE, et al. Comparative effectiveness of induction therapy for human immunodeficiency virus-associated cryptococcal meningitis: A network meta-analysis. *Open Forum Infect Dis* **2015**; 2, doi: 10.1093/ofid/ofv010.
3. Sun X, Briel M, Busse JW, et al. Credibility of claims of subgroup effects in randomised

controlled trials: systematic review. *BMJ* **2012**; 344:e1553.

4. Day JN, Chau TT, Wolbers M, et al. Combination antifungal therapy for cryptococcal meningitis. *N Engl J Med* **2013**; 368:1291–302.
5. van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. *N Engl J Med* **1997**; 337:15–21.
6. Milani B, Ford N. Responding to the evidence for improved treatment for cryptococcal meningitis in resource-limited settings. *S Afr Med J* **2012**; 102:196–7.
7. Loyse A, Dromer F, Day J, et al. Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. *J Antimicrob Chemother* **2013**; 68:2435–44.

Correspondence: Mark J. Siedner, MD, MPH, 55 Fruit Street, GRJ5, Boston, MA 02114 (msiedner@partners.org).

Open Forum Infectious Diseases

Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US. DOI: 10.1093/ofid/ofv071